TGF-β in Renal Injury and Disease

Seminars in Nephrology

Volumn 27, Issue 3, 2007, Pages 309-320

  Böttinger, Erwin P ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

apoptosis; cell biology; chronic kidney disease; Fibrosis; signal transduction

Indexed keywords

CYTOKINE; PENTOXIFYLLINE; PIRFENIDONE; TRANSFORMING GROWTH FACTOR BETA;

APOPTOSIS; ARTICLE; CELL TRANSFORMATION; DISEASE COURSE; FIBROGENESIS; HUMAN; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY INJURY; NONHUMAN; PRIORITY JOURNAL; TISSUE REPAIR;

ANIMALS; FIBROSIS; HUMANS; KIDNEY DISEASES; MODELS, BIOLOGICAL; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA;

EID: 34249052234     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.02.009     Document Type: Article

References (121)

1. Roberts A.B., and Sporn M.B. The transforming growth factors-β. In: Sporn M.B., and Roberts A.B. (Eds). Handbook of experimental pharmacology. Peptide growth factors and their receptors. 95th ed. (1990), Springer-Verlag, Berlin 419-472
2. de Larco J.E., and Todaro G.J. Growth factors from murine sarcoma virus-transformed cells. Proc Natl Acad Sci U S A 75 (1978) 4001-4005
3. Roberts A.B., Anzano M.A., Lamb L.C., Smith J.M., and Sporn M.B. New class of transforming growth factors potentiated by epidermal growth factor: isolation from non-neoplastic tissues. Proc Natl Acad Sci U S A 78 (1981) 5339-5343
4. Moses H.L., and Serra R. Regulation of differentiation by TGF-beta. Curr Opin Genet Dev 6 (1996) 581-586
5. Massague J. The transforming growth factor-beta family. Annu Rev Cell Biol 6 (1990) 597-641
6. Chang H., Brown C.W., and Matzuk M.M. Genetic analysis of the mammalian transforming growth factor-beta superfamily. Endocr Rev 23 (2002) 787-823
7. Rifkin D.B. Latent transforming growth factor-beta (TGF-beta) binding proteins: orchestrators of TGF-beta availability. J Biol Chem 280 (2005) 7409-7412
8. Derynck R., and Zhang Y.E. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425 (2003) 577-584
9. Shi Y., and Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 113 (2003) 685-700
10. ten Dijke P., and Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 29 (2004) 265-273
11. Wrana J.L., Attisano L., Wieser R., Ventura F., and Massague J. Mechanism of activation of the TGF-beta receptor. Nature 370 (1994) 341-347
12. Goumans M.J., Lebrin F., and Valdimarsdottir G. Controlling the angiogenic switch: a balance between two distinct TGF-b receptor signaling pathways. Trends Cardiovasc Med 13 (2003) 301-307
13. Kavsak P., Rasmussen R.K., Causing C.G., Bonni S., Zhu H., Thomsen G.H., et al. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. Mol Cell 6 (2000) 1365-1375
14. Bottinger E.P., and Bitzer M. TGF-β signaling in renal disease. J Am Soc Nephrol 13 (2002) 2600-2610
15. Roberts A.B., Sporn M.B., Assoian R.K., Smith J.M., Roche N.S., Wakefield L.M., et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci U S A 83 (1986) 4167-4171
16. Kehrl J.H., Roberts A.B., Wakefield L.M., Jakowlew S., Sporn M.B., and Fauci A.S. Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes. J Immunol 137 (1986) 3855-3860
17. Wahl S.M., Hunt D.A., Wakefield L.M., McCartney-Francis N., Wahl L.M., Roberts A.B., et al. Transforming growth factor type beta induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci U S A 84 (1987) 5788-5792
18. Van Obberghen-Schilling E., Roche N.S., Flanders K.C., Sporn M.B., and Roberts A.B. Transforming growth factor beta 1 positively regulates its own expression in normal and transformed cells. J Biol Chem 263 (1988) 7741-7746
19. Border W.A., Okuda S., Languino L.R., Sporn M.B., and Ruoslahti E. Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature 346 (1990) 371-374
20. Giri S.N., Hyde D.M., and Hollinger M.A. Effect of antibody to transforming growth factor beta on bleomycin induced accumulation of lung collagen in mice. Thorax 48 (1993) 959-966
21. Sporn M.B., and Roberts A.B. Peptide growth factors and inflammation, tissue repair, and cancer. J Clin Invest 78 (1986) 329-332
22. Moses H.L., Yang E.Y., and Pietenpol J.A. TGF-beta stimulation and inhibition of cell proliferation: new mechanistic insights. Cell 63 (1990) 245-247
23. Hostetter T.H., Olson J.L., Rennke H.G., Venkatachalam M.A., and Brenner B.M. Hyperfiltration in remnant nephrons: a potentially adverse response to renal ablation. Am J Physiol 241 (1981) F85-F93
24. Hostetter T.H., Troy J.L., and Brenner B.M. Glomerular hemodynamics in experimental diabetes mellitus. Kidney Int 19 (1981) 410-415
25. Dunn B.R., Anderson S., and Brenner B.M. The hemodynamic basis of progressive renal disease. Semin Nephrol 6 (1986) 122-138
26. Anderson S., Rennke H.G., and Brenner B.M. Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 77 (1986) 1993-2000
27. Anderson S., and Brenner B.M. Intraglomerular hypertension: implications and drug treatment. Annu Rev Med 39 (1988) 243-253
28. Wolf G., Mueller E., Stahl R.A., and Ziyadeh F.N. Angiotensin II-induced hypertrophy of cultured murine proximal tubular cells is mediated by endogenous transforming growth factor-beta. J Clin Invest 92 (1993) 1366-1372
29. Kagami S., Border W.A., Miller D.E., and Noble N.A. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 93 (1994) 2431-2437
30. Okuda S., Languino L.R., Ruoslahti E., and Border W.A. Elevated expression of transforming growth factor-beta and proteoglycan production in experimental glomerulonephritis. Possible role in expansion of the mesangial extracellular matrix. [published erratum appears in J Clin Invest 1990;86:2175]. J Clin Invest 86 (1990) 453-462
31. Yamamoto T., Nakamura T., Noble N.A., Ruoslahti E., and Border W.A. Expression of transforming growth factor beta is elevated in human and experimental diabetic nephropathy. Proc Natl Acad Sci U S A 90 (1993) 1814-1818
32. Sharma K., and Ziyadeh F.N. Renal hypertrophy is associated with upregulation of TGF-beta 1 gene expression in diabetic BB rat and NOD mouse. Am J Physiol 267 (1994) F1094-F1101
33. Border W.A., and Noble N.A. Transforming growth factor beta in tissue fibrosis. N Engl J Med 331 (1994) 1286-1292
34. Bitzer M., Sterzel R.B., and Bottinger E.P. Transforming growth factor-beta in renal disease. Kidney Blood Press Res 21 (1998) 1-12
35. Ketteler M., Noble N.A., and Border W.A. Transforming growth factor-beta and angiotensin II: the missing link from glomerular hyperfiltration to glomerulosclerosis?. Annu Rev Physiol 57 (1995) 279-295
36. Noble N.A., and Border W.A. Angiotensin II in renal fibrosis: should TGF-beta rather than blood pressure be the therapeutic target?. Sem Nephrol 17 (1997) 455-466
37. Ziyadeh F.N. Mediators of diabetic renal disease: the case for TGF-beta as the major mediator. J Am Soc Nephrol 15 Suppl 1 (2004) 55-57
38. Petermann A.T., Hiromura K., Blonski M., Pippin J., Monkawa T., Durvasula R., et al. Mechanical stress reduces podocyte proliferation in vitro. Kidney Int 61 (2002) 40-50
39. Topper J.N., Cai J., Qiu Y., Anderson K.R., Xu Y.Y., Deeds J.D., et al. Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. Proc Natl Acad Sci U S A 94 (1997) 9314-9319
40. Cortes P., Riser B., and Narins R.G. Glomerular hypertension and progressive renal disease: the interplay of mesangial cell stretch, cytokine formation and extracellular matrix synthesis. Contrib Nephrol 118 (1996) 229-233
41. Sotoudeh M., Li Y.S., Yajima N., Chang C.C., Tsou T.C., Wang Y., et al. Induction of apoptosis in vascular smooth muscle cells by mechanical stretch. Am J Physiol 282 (2002) H1709-H1716
42. Border W.A., Noble N.A., Yamamoto T., Harper J.R., Yamaguchi Yu., Pierschbacher M.D., et al. Natural inhibitor of transforming growth factor-beta protects against scarring in experimental kidney disease. Nature 360 (1992) 361-364
43. Isaka Y., Brees D.K., Ikegaya K., Kaneda Y., Imai E., Noble N.A., et al. Gene therapy by skeletal muscle expression of decorin prevents fibrotic disease in rat kidney. Nat Med 2 (1996) 418-423
44. Sharma K., Jin Y., Guo J., and Ziyadeh F.N. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 45 (1996) 522-530
45. Isaka Y., Akagi Y., Ando Y., Tsujie M., Sudo T., Ohno N., et al. Gene therapy by transforming growth factor-beta receptor-IgG Fc chimera suppressed extracellular matrix accumulation in experimental glomerulonephritis. Kidney Int 55 (1999) 465-475
46. Ziyadeh F.N., Hoffman B.B., Han D.C., Iglesias-de la Cruz M.C., Hong S.W., Isono M., et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci U S A 97 (2000) 8015-8020
47. Rocco M.V., Chen Y., Goldfarb S., and Ziyadeh F.N. Elevated glucose stimulates TGF-beta gene expression and bioactivity in proximal tubule. Kidney Int 41 (1992) 107-114
48. Grygielko E.T., Martin W.M., Tweed C., Thornton P., Harling J., Brooks D.P., et al. Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther 313 (2005) 943-951
49. Isaka Y., Fujiwara Y., Ueda N., Kaneda Y., Kamada T., and Imai E. Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest 92 (1993) 2597-2601
50. Sanderson N., Factor V., Nagy P., Kopp J., Kondaiah P., Wakefield L., et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci U S A 92 (1995) 2572-2576
51. Bottinger E.P., and Kopp J.B. Lessons from TGF-beta transgenic mice. Miner Electrolyte Metab 24 (1998) 154-160
52. Schiffer M., Bitzer M., Roberts I.S., Kopp J.B., ten Dijke P., Mundel P., et al. Apoptosis in podocytes induced by TGF-beta and Smad7. J Clin Invest 108 (2001) 807-816
53. Sato M., Muragaki Y., Saika S., Roberts A.B., and Ooshima A. Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112 (2003) 1486-1494
54. Fujimoto M., Maezawa Y., Yokote K., Joh K., Kobayashi K., Kawamura H., et al. Mice lacking Smad3 are protected against streptozotocin-induced diabetic glomerulopathy. Biochem Biophys Res Commun 305 (2003) 1002-1007
55. Terada Y., Hanada S., Nakao A., Kuwahara M., Sasaki S., and Marumo F. Gene transfer of Smad7 using electroporation of adenovirus prevents renal fibrosis in post-obstructed kidney. Kidney Int 61 (2002) 94-98
56. Hou C.C., Wang W., Huang X.R., Fu P., Chen T.H., Sheikh-Hamad D., et al. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-{beta} signaling and fibrosis in rat remnant kidney. Am J Pathol 166 (2005) 761-771
57. Verrecchia F., and Mauviel A. Control of connective tissue gene expression by TGF beta: role of Smad proteins in fibrosis. Curr Rheumatol Rep 4 (2002) 143-149
58. Schnaper H.W., and Kopp J.B. Renal fibrosis. Front Biosci 8 (2003) e68-e86
59. Vindevoghel L., Lechleider R.J., Kon A., de Caestecker M.P., Uitto J., Roberts A.B., et al. SMAD3/4-dependent transcriptional activation of the human type VII collagen gene (COL7A1) promoter by transforming growth factor beta. Proc Natl Acad Sci U S A 95 (1998) 14769-14774
60. Verrecchia F., Vindevoghel L., Lechleider R.J., Uitto J., Roberts A.B., and Mauviel A. Smad3/AP-1 interactions control transcriptional responses to TGF-beta in a promoter-specific manner. Oncogene 20 (2001) 3332-3340
61. Chung K.Y., Agarwal A., Uitto J., and Mauviel A. An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem 271 (1996) 3272-3278
62. Poncelet A.C., de Caestecker M.P., and Schnaper H.W. The transforming growth factor-beta/SMAD signaling pathway is present and functional in human mesangial cells. Kidney Int 56 (1999) 1354-1365
63. Wang W., Huang X.R., Canlas E., Oka K., Truong L.D., Deng C., et al. Essential role of Smad3 in angiotensin II-induced vascular fibrosis. Circ Res 98 (2006) 1032-1039
64. Yang Y.C., Piek E., Zavadil J., Liang D., Xie D., Heyer J., et al. Hierarchical model of gene regulation by transforming growth factor beta. Proc Natl Acad Sci U S A 100 (2003) 10269-10274
65. Hubchak S.C., Runyan C.E., Kreisberg J.I., and Schnaper H.W. Cytoskeletal rearrangement and signal transduction in TGF-beta1-stimulated mesangial cell collagen accumulation. J Am Soc Nephrol 14 (2003) 1969-1980
66. Runyan C.E., Schnaper H.W., and Poncelet A.C. The phosphatidylinositol 3-kinase/Akt pathway enhances Smad3-stimulated mesangial cell collagen I expression in response to transforming growth factor-beta1. J Biol Chem 279 (2004) 2632-2639
67. Wang L., Ma R., Flavell R.A., and Choi M.E. Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells. J Biol Chem 277 (2002) 47257-47262
68. Daniels C.E., Wilkes M.C., Edens M., Kottom T.J., Murphy S.J., Limper A.H., et al. Imatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114 (2004) 1308-1316
69. Wang S., Wilkes M.C., Leof E.B., and Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-beta pathway and reduces renal fibrogenesis in vivo. FASEB J 19 (2005) 1-11
70. Igarashi A., Okochi H., Bradham D.M., and Grotendorst G.R. Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 4 (1993) 637-645
71. Lasky J.A., Ortiz L.A., Tonthat B., Hoyle G.W., Corti M., Athas G., et al. Connective tissue growth factor mRNA expression is upregulated in bleomycin-induced lung fibrosis. Am J Physiol 275 (1998) L365-L371
72. McCarron R.M., Wang L., Racke M.K., McFarlin D.E., and Spatz M. Cytokine-regulated adhesion between encephalitogenic T lymphocytes and cerebrovascular endothelial cells. J Neuroimmunol 43 (1993) 23-30
73. Paradis V., Dargere D., Vidaud M., De Gouville A.C., Huet S., Martinez V., et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 30 (1999) 968-976
74. Mori T., Kawara S., Shinozaki M., Hayashi N., Kakinuma T., Igarashi A., et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 181 (1999) 153-159
75. Roberts A.B., Tian F., Byfield S.D., Stuelten C., Ooshima A., Saika S., et al. Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. Cytokine Growth Factor Rev 17 (2006) 19-27
76. Verrecchia F., Tacheau C., Wagner E.F., and Mauviel A. A central role for the JNK pathway in mediating the antagonistic activity of pro-inflammatory cytokines against transforming growth factor-beta-driven SMAD3/4-specific gene expression. J Biol Chem 278 (2003) 1585-1593
77. Bitzer M., von Gersdorff G., Liang D., Dominguez-Rosales A., Beg A.A., Rojkind M., et al. A mechanism of suppression of TGF-beta/SMAD signaling by NF-kappaB/RelA. Genes Dev 14 (2000) 187-197
78. Ulloa L., Doody J., and Massague J. Inhibition of transforming growth factor-beta/SMAD signalling by the interferon-gamma/STAT pathway. Nature 397 (1999) 710-713
79. Hui A.Y., Dannenberg A.J., Sung J.J., Subbaramaiah K., Du B., Olinga P., et al. Prostaglandin E2 inhibits transforming growth factor beta 1-mediated induction of collagen alpha 1(I) in hepatic stellate cells. J Hepatol 41 (2004) 251-258
80. Canbay A., Friedman S., and Gores G.J. Apoptosis: the nexus of liver injury and fibrosis. Hepatology 39 (2004) 273-278
81. Selman M., and Pardo A. The epithelial/fibroblastic pathway in the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 29 (2003) S93-S97
82. Savill J. Apoptosis and renal injury. Curr Opin Nephrol Hypertens 4 (1995) 263-269
83. Kumar D., Robertson S., and Burns K.D. Evidence of apoptosis in human diabetic kidney. Mol Cell Biochem 259 (2004) 67-70
84. Schiffer M., Mundel P., Shaw A.S., and Bottinger E.P. A novel role for the adaptor molecule CD2-associated protein in TGF-beta-induced apoptosis. J Biol Chem 279 (2004) 37004-37012
85. Susztak K., Ciccone E., McCue P., Sharma K., and Bottinger E.P. Multiple metabolic hits converge on CD36 as novel mediator of tubular epithelial apoptosis in diabetic nephropathy. PLoS Med 2 (2005) e45
86. Fadok V.A., Bratton D.L., Konowal A., Freed P.W., Westcott J.Y., and Henson P.M. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 101 (1998) 890-898
87. Canbay A., Feldstein A.E., Higuchi H., Werneburg N., Grambihler A., Bronk S.F., et al. Kupffer cell engulfment of apoptotic bodies stimulates death ligand and cytokine expression. Hepatology 38 (2003) 1188-1198
88. Canbay A., Taimr P., Torok N., Higuchi H., Friedman S., and Gores G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 83 (2003) 655-663
89. Savill J., Smith J., Sarraf C., Ren Y., Abbott F., and Rees A. Glomerular mesangial cells and inflammatory macrophages ingest neutrophils undergoing apoptosis. Kidney Int 42 (1992) 924-936
90. Arsalane K., Dubois C.M., Muanza T., Begin R., Boudreau F., Asselin C., et al. Transforming growth factor-beta1 is a potent inhibitor of glutathione synthesis in the lung epithelial cell line A549: transcriptional effect on the GSH rate-limiting enzyme gamma-glutamylcysteine synthetase. Am J Respir Cell Mol Biol 17 (1997) 599-607
91. Budinger G.R., Mutlu G.M., Eisenbart J., Fuller A.C., Bellmeyer A.A., Baker C.M., et al. Proapoptotic Bid is required for pulmonary fibrosis. Proc Natl Acad Sci U S A 103 (2006) 4604-4609
92. Kuwano K., Kunitake R., Maeyama T., Hagimoto N., Kawasaki M., Matsuba T., et al. Attenuation of bleomycin-induced pneumopathy in mice by a caspase inhibitor. Am J Physiol 280 (2001) L316-L325
93. Uhal B.D., Rayford H., Zhuang J., Li X., Laukka J., and Soledad-Conrad V. Apoptosis-dependent acute lung injury and repair after intratracheal instillation of noradrenaline in rats. Exp Physiol 88 (2003) 269-275
94. Lee C.G., Kang H.R., Homer R.J., Chupp G., and Elias J.A. Transgenic modeling of transforming growth factor-beta(1): role of apoptosis in fibrosis and alveolar remodeling. Proc Am Thorac Soc 3 (2006) 418-423
95. Takehara T., Tatsumi T., Suzuki T., Rucker III E.B., Hennighausen L., Jinushi M., et al. Hepatocyte-specific disruption of Bcl-xL leads to continuous hepatocyte apoptosis and liver fibrotic responses. Gastroenterology 127 (2004) 1189-1197
96. Kim Y.H., Goyal M., Kurnit D., Wharram B., Wiggins J., Holzman L., et al. Podocyte depletion and glomerulosclerosis have a direct relationship in the PAN-treated rat. Kidney Int 60 (2001) 957-968
97. Wharram B.L., Goyal M., Wiggins J.E., Sanden S.K., Hussain S., Filipiak W.E., et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol (2005)
98. Kelly D.J., Cox A.J., Tolcos M., Cooper M.E., Wilkinson-Berka J.L., and Gilbert R.E. Attenuation of tubular apoptosis by blockade of the renin-angiotensin system in diabetic Ren-2 rats. Kidney Int 61 (2002) 31-39
99. Schaefer L., Mihalik D., Babelova A., Krzyzankova M., Grone H.J., Iozzo R.V., et al. Regulation of fibrillin-1 by biglycan and decorin is important for tissue preservation in the kidney during pressure-induced injury. Am J Pathol 165 (2004) 383-396
100. Thiery J.P. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 15 (2003) 740-746
101. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112 (2003) 1776-1784
102. Yang J., and Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 159 (2001) 1465-1475
103. Zavadil J., and Bottinger E.P. TGF-beta and epithelial-to-mesenchymal transitions. Oncogene 24 (2005) 5764-5774
104. Iwano M., Plieth D., Danoff T.M., Xue C., Okada H., and Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest 110 (2002) 341-350
105. Kaneto H., Morrissey J., and Klahr S. Increased expression of TGF-beta 1 mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 44 (1993) 313-321
106. Morrissey J., Guo G., Moridaira K., Fitzgerald M., McCracken R., Tolley T., et al. Transforming growth factor-beta induces renal epithelial jagged-1 expression in fibrotic disease. J Am Soc Nephrol 13 (2002) 1499-1508
107. Rastaldi M.P., Ferrario F., Giardino L., Dell'Antonio G., Grillo C., Grillo P., et al. Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62 (2002) 137-146
108. Vongwiwatana A., Tasanarong A., Rayner D.C., Melk A., and Halloran P.F. Epithelial to mesenchymal transition during late deterioration of human kidney transplants: the role of tubular cells in fibrogenesis. Am J Transplant 5 (2005) 1367-1374
109. Oldfield M.D., Bach L.A., Forbes J.M., Nikolic-Paterson D., McRobert A., Thallas V., et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 108 (2001) 1853-1863
110. Willis B.C., Liebler J.M., Luby-Phelps K., Nicholson A.G., Crandall E.D., du Bois R.M., et al. Induction of epithelial-mesenchymal transition in alveolar epithelial cells by transforming growth factor-beta1: potential role in idiopathic pulmonary fibrosis. Am J Pathol 166 (2005) 1321-1332
111. Yingling J.M., Blanchard K.L., and Sawyer J.S. Development of TGF-beta signalling inhibitors for cancer therapy. Nat Rev Drug Discov 3 (2004) 1011-1022
112. Laping N.J. ALK5 inhibition in renal disease. Curr Opin Pharmacol 3 (2003) 204-208
113. Yang Y.A., Dukhanina O., Tang B., Mamura M., Letterio J.J., MacGregor J., et al. Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. J Clin Invest 109 (2002) 1607-1615
114. Ruzek M.C., Hawes M., Pratt B., McPherson J., Ledbetter S., Richards S.M., et al. Minimal effects on immune parameters following chronic anti-TGF-beta monoclonal antibody administration to normal mice. Immunopharmacol Immunotoxicol 25 (2003) 235-257
115. Pines M., and Nagler A. Halofuginone: a novel antifibrotic therapy. Gen Pharmacol 30 (1998) 445-450
116. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K.C., et al. Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem 279 (2004) 15167-15176
117. Lin S.L., Chen R.H., Chen Y.M., Chiang W.C., Lai C.F., Wu K.D., et al. Pentoxifylline attenuates tubulointerstitial fibrosis by blocking Smad3/4-activated transcription and profibrogenic effects of connective tissue growth factor. J Am Soc Nephrol 16 (2005) 2702-2713
118. Shihab F.S., Bennett W.M., Yi H., and Andoh T.F. Pirfenidone treatment decreases transforming growth factor-beta1 and matrix proteins and ameliorates fibrosis in chronic cyclosporine nephrotoxicity. Am J Transplant 2 (2002) 111-119
119. Mizuno S., Kurosawa T., Matsumoto K., Mizuno-Horikawa Y., Okamoto M., and Nakamura T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J Clin Invest 101 (1998) 1827-1834
120. Zeisberg M., Bottiglio C., Kumar N., Maeshima Y., Strutz F., Muller G.A., et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol 285 (2003) F1060-F1067
121. Zeisberg M., Hanai J., Sugimoto H., Mammoto T., Charytan D., Strutz F., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 9 (2003) 964-968